Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-24
2007-04-24
Kerr, Kathleen M. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S399000, C530S840000, C424S093700
Reexamination Certificate
active
11086628
ABSTRACT:
We claim a method of treating a patient to stimulate chondrocyte proliferation comprising administering to said patient an adrenomedullin analog that is adrenomedullin-(27–52) wherein said patient is suffering from cartilage disorders, and a method of stimulating chondrocyte proliferation comprising administering to chondrocyte cells adrenomedullin-(27–52).
REFERENCES:
patent: 5478847 (1995-12-01), Draper
patent: 5888963 (1999-03-01), Coy et al.
patent: 6294359 (2001-09-01), Fiddes et al.
patent: 6440421 (2002-08-01), Cornish et al.
patent: 6544949 (2003-04-01), Dong
patent: 6821954 (2004-11-01), Reid et al.
patent: 6869926 (2005-03-01), Reid et al.
patent: 0 622 458 (1994-11-01), None
patent: 0 408 284 (1996-05-01), None
patent: WO 96/02269 (1996-02-01), None
patent: WO 9602269 (1996-02-01), None
patent: WO 97/07214 (1997-02-01), None
patent: WO 97/38704 (1997-10-01), None
patent: WO 99/16406 (1999-04-01), None
Kuwasako et al. (2001) The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors. J. Biol. Chem. vol. 276, No. 52, pp. 49459-49465.
Nakamura et al. (2005) Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection. J. Mol. Endocrinol. vol. 34, No. 1, pp. 257-261.
Takahashi, K. (2001) Adrenomedullin from a pheochromocytoma to the eye: implications of the adrenomedullin research for endocrinology in the 21st century. Tohoku J. Exp. Med. vol. 193, No. 2, pp. 79-114.
Cornish et al. (2002) Amylin and adrenomedullin: novel regulators of bone growth. Curr. Pharm. Des. vol. 8, No. 23, pp. 2009-2021.
Smith et al. (2002) Adrenomedullin: receptor and signal transduction. Biochem. Soc. Trans. vol. 30, issue 4, pp. 432-437.
Cornish et al. (1995) Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem. Biophys. Res. Commun. vol. 207, No. 1, pp. 133-139.
Zimmermann et al. (1996) Identification of adrenomedullin receptors in cultured rat astrocytes and in neuroblastboma x glioma hybrid cells (NG108-15). Brain Res. vol. 724, No. 2, pp. 238-245.
Cornish et al. (2000) Systemic administration of a novel octapeptide, amylin-(1-8), increases bone volume in male mice. Am. J. Physiol. Endocrinol. Metab. vol. 279, issue 4, pp. E730-E735.
Christopoulos et al. “Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product”Mol. Pharmacol. 56:235-242 (1999).
Cornish et al. “Adrenomedullin is a Potent Simulator of Osteoblastic Activity In Vitro and In Vivo”Am. J. Physiol. 273:E1113-E1120 (1997).
Cornish et al. “Dissociation of the effects of amylin on osteoblast proliferation and bone resorption”Am. J. Physiol. 274:E827-E833 (1998).
Cornish et al. “Systemic Administration of Amylin Increases Bone Mass, Linear Growth, and Adiposity in Adult Male Mice”Am. J. Physiol. 275:E694-E699 (1998).
Fisher et al. “Functional relevance of G-protein-coupled-receptor-associate proteins, exemplified by receptor-activity-modifying proteins (RAMPs)”Biochem. Soc. Trans. Review30:455-460 (2002).
Ng et al. “Familial early-onset type 2 diabetes in Chinese patients: obesity and genetics have more significant roles than autoimmunity”Diabetes Care24:663-671 (2001).
Reid et al. “Amylin and CGRP”Principles of Bone Biol. 495-505 (1996).
Fackson et al., “A Possible Regulatory Function of Amylin on the Mineralization of Growth Plate Chondrocytes”Faseb J. 7(7):A1238 (1993).
Belloni et al., “Inhibitory Effect of Adrenomedullin (ADM) on the Aldosterone Response of Human Adrenocorticol Cells to Angiotensin-II: Role of ADM(22-52)-Sensitive Receptors”Life Sciences, 63(26):2313-2321 (1998).
Cheng et al., “Synthetic Human Adrenomedullin and ADM15-52 Have Potent Short-Lasting Vasodilator Activity In The Pulmonary Vascular Bed of the Cat”Life Sciences55:PL251-PL256 (1994).
Cornish et al., “Skeletal Effects of Amylin and Related Peptides”Endocrinologist9:183-189 (1999).
Cornish et al., “Systemic administration of adrenomedullin (27-52) increase bone volume and strength in male mice”J. Endocrinol., 170:251-257 (2001).
Cornish et al., “Amylin Stimulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice”Biochem.&Biophys. Res. Comm., 207(1):133-139 (1995).
DeWitt et al., “Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the pulmonary vascular bed of the cat”Eur. J. Pharmacol., 257:303-306 (1996).
Eguchi et al., “Structure-Activity Relationship of Adrenomedullin, a Novel Vasodilatory Peptide, in Cultured Rat Vascular Smooth Muscle Cells”Endocrinology, 135:2454-2458 (1994).
Cuttitta et al., EMBL Accession No. AAW25159; Dec. 8, 1997.
Hao et al., “An Adrenomedullin (ADM) Fragment Retains the Systemic Vasodilator Activity of Human ADM”Life Sciences, 54:PL265-PL270 (1994).
Hinson et al., “Adrenomedullin, a Multifunctional Regulatory Peptide”Endocrine Reviews21(2):138-167 (2000).
Ichiki et al., “Distribution and Characterization of Immunoreactive Adrenomedullin in Human Tissue and Plasma”FEBS Letters338:6-10 (1994).
Ishiyama et al., “Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats”Eur. J. of Pharmacol., 241;271-273 (1993).
Kanazawa et al., “Adrenomedullin, A Newly Discovered Hypotensive Peptide, is a Potent Bronchodilator” 205:251-254 (1994).
Kitamura et al., “Adrenomedullin: A Novel Hypotensive Peptide Isolated From Human Pheochromocytoma”Biochem.&Biophys. Res. Commun., 192:553-560 (1993).
Kitamura, et al., “Cloning and Characterization of cDNA Encoding a Precursor for Human Adrenomedullin”Biochem.&Biophys. Res. Commun., 194(2):720-725 (1993).
Kitamura et al., “Complete Amino Acid Sequence of Porcine Adrenomedullin and Cloning of cDNA Encoding its Precursor”FEBS Letters, 338:306-310 (1994).
Lin et al., “An Adrenomedullin Fragment Retains the Systemic Vasodepressor Activity of Rat Adrenomedullin”Eur. J. Pharmacol., 260:1-4 (1994).
Lippton et al., “Adrenomedullin dilates the pulmonary vascular bed in vivo”J. Appl. Physiol., 76:2154-2156 (1994).
Muff et al., “Calcitonin, Calcitonin Gene-related Peptide, Adrenomedullin and Amylin: Homologous Peptides, Separate Receptors and Overlapping Biological Actions”Eur. J. Endocrinol., 133:17-20 (1995).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”The Protein Folding Problem and Tertiary Structure Prediction491-495 (1994).
Nuki, et al., “Vasodilator Effect of Adrenomedullin and Calcitonin Gene-Related Peptide Receptors in Rat Mesenteric Vascular Beds”Biochem.&Biophys. Res. Comm., 196:245-251 (1993).
Owji et al., “An Abundant and Specific Binding Site for the Novel Vasodilator Adrenomedullin in the Rat”,Endocrinology, 136:2127-2134 (1995).
Perret et al., “The Effect of Adrenomedullin on the Isolated Heart”Life Sciences, 53:PL377-379 (1993).
Sakata et al., “Molecular Cloning and Biological Activities of Rat Adrenomedullin, A Hypotensive Peptide”Biochem.&Biophys. Res. Commun., 195:921-927 (1993).
Santiago et al., “Comparison of Responses to Adrenomedullin and Adrenomedullin Analogs in the Mesenteric Vascular Bed of the Cat”Eur. J. Pharmacol., 272:115-118 (1995).
Santiago et al., “Synthetic Human Adrenomedullin and Adrenomedullin 15-52 Have Potent Short-Lived Vasodilator Activity in the Hindlimb Vascular Bed of the Cat”Life Sciences, 55:PL85-PL90 (1994).
Schmidt et al., “Replacement of N-Terminal Portions of TGF-α with Corresponding Heregulin Sequences affects Ligand-Induced Receptor Signaling and Intoxication of Tumor Cells by Chimeric
Cornish Jillian
Reid Ian Reginald
Auckland UniServices Limited
Fish & Richardson P.C.
Kerr Kathleen M.
Liu Samuel W
LandOfFree
Therapeutic method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796791